Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | PROMISE: MGUS/SMM screening study

Irene Ghobrial • 4 Dec 2018
ASH 2018
Multiple Myeloma Rare Diseases Smoldering Myeloma
PROMISE

Irene Ghobrial, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the new PROMISE study (NCT03689595), aiming to determine the clinical and genomic alterations present in individuals with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) through screening those at high risk due to a family history or ethnicity. Dr Ghobrial, speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, shares the biggest myeloma screening study ever run to help prevent progression from occurring by catching the disease at an early stage.

More from Irene Ghobrial

0:52
Using spatial proteomics to analyze the bone marrow microenvironment in SMM treated with nivolumab
Irene Ghobrial • 7 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:04
Early interception in SMM & novel agents being explored
Irene Ghobrial et al. • 25 Mar 2024
1:19
Single-cell sequencing of circulating tumor cells to predict progression from MGUS/SMM
Irene Ghobrial • 11 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals